Format

Send to

Choose Destination
Am J Perinatol. 2015 May;32(6):565-70. doi: 10.1055/s-0034-1543955. Epub 2015 Jan 16.

Rifampin use and safety in hospitalized infants.

Author information

1
Duke Clinical Research Institute, Durham, North Carolina.
2
Pediatrix Medical Group, Sunrise, Florida.

Abstract

OBJECTIVE:

This study aims to examine the use and safety of rifampin in the hospitalized infants.

STUDY DESIGN:

Observational study of clinical and laboratory adverse events among infants exposed to rifampin from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012.

RESULT:

Overall, 2,500 infants received 4,279 courses of rifampin; mean gestational age was 27 weeks (5th, 95th percentile; 23, 36) and mean birth weight was 1,125 g (515; 2,830). Thrombocytopenia (121/1,000 infant days) and conjugated hyperbilirubinemia (25/1,000 infant days) were the most common laboratory adverse events. The most common clinical adverse events were medical necrotizing enterocolitis (64/2,500 infants, 3%) and seizure (60/2,500 infants, 2%).

CONCLUSION:

The overall incidence of adverse events among infants receiving rifampin appears low; however, additional studies to further evaluate safety and dosing of rifampin in this population are needed.

PMID:
25594217
PMCID:
PMC4433596
DOI:
10.1055/s-0034-1543955
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York Icon for PubMed Central
Loading ...
Support Center